Drug intelligence / Profile preview

RZB 014

Development stage: Preclinical
Lead developer: Unicycive Therapeutics
Administration: Subcutaneous

Overview

RZB 014 is a drug candidate acquired by Unicycive Therapeutics from Spectrum Pharmaceuticals in September 2018. It is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. RZB 014 is described as a compound related to Renazorb (RZB 012), another asset acquired in the same deal.

Targets

Pi (Inorganic phosphate)

Beyond the preview

Go deeper on RZB 014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RZB 014.

Explore the full profile